Next-generation sequencing (NGS) biomarker testing for all newly diagnosed non-squamous non-small cell lung cancer (NSCLC) was introduced nationwide in Slovenia in 2022. Between 2022 and 2024, 2,559 patient samples (mean age 70 years; 52% male) were analyzed using the Thermo Fisher Oncomine Precision Assay on the Genexus® System. Targetable driver alterations were detected in 59% of cases, more often in women (67% vs. 52% in men), with no significant age-related differences. The distribution of genetic alterations in Slovenian non-squamous NSCLC patients aligns with patterns observed in other European populations, providing the first comprehensive national overview of actionable biomarkers in this disease.
Published for ESMO 2025.
Katja Mohorčič1,2, Roman Luštrik3, Izidor Kern4, Mitja Rot4, Mark Uhlik5, Žan Kuralt6, Luka Ausec5, Jasna But Hadžić7,2
1 Medical Oncology Unit, University Clinic Golnik, Slovenia
2 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
3 Biolitika – Roman Luštrik s.p., Ljubljana
4 Pathology Department, University Clinic Golnik, Slovenia
5 Genialis, Inc., Boston, MA, USA
6 Genialis, d.o.o., Ljubljana, Slovenia,
7 Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia
